Patent US4795423A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4795423A Expired / Lapsed US ⏱️ 0.0 years remaining

Oxygenated perfluorinated perfusion of the ocular globe to treat ischemic retinopathy

Assignee: Thomas Jefferson University
•
Filing: 1986-08-28
•
Granted: 1989-01-03
•
Expires: 2006-08-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A novel method of treating ischemic retinopathy is disclosed. After diagnosis of ischemic retinopathy, as for example as a result of retinal infarction, the ocular globe is penetrated with two small cannulae. An inflow and outflow perfusion is then established with an oxygenated perfluorochemical emulsion or other physiologically compatible oxygenated liquid. A sufficient perfusion rate is established and maintained to provide the metabolic needs of the retina for the 3 to 5 day period necessary to permit the natural healing process to occur. The method comprises removing at least a portion of vitreous body to create an intraocular perfusion space and establishing a perfusion of physiologically compatible oxygenated fluid through that perfusion space at a rate and for a duration sufficient to permit the natural healing process to occur. Alternatively, a method of diagnosing the condition of retinal tissue suspected of being ischemic is disclosed.

Inventors

  • 👤 Jewell L. Osterholm

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 20:25
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A61B; A61B17/00; A61B17/16; A61B17/17; A61B17/1739; A61B17/34; A61B17/3403; A61K31/00; A61K31/02; A61K31/33; A61K31/335; A61K31/34; A61K9/0029; A61M; A61M25/00; A61M25/01; A61M25/02; A61M3/00; A61M3/02; A61M3/0204; A61M3/0212; A61M1/00; A61M1/14; A61M1/28; A61M1/287; A61M1/32; A61M2025/0213; A61M2025/028; A61M2202/00; A61M2202/04; A61M2202/0464; A61M2202/0468; A61M2202/0476; A61M2205/00; A61M2205/36; A61M2205/3653; A61M2210/00; A61M2210/06; A61M2210/0693

Claims Analysis

Total Claims: 39
Claim 1
Independent Claim 53 words
A method of treating retinal ischemia, comprising the steps of: a. removing at least a portion of the vitreous body to create an intra-ocular perfusion space; and b. establising a circulation of a physiologically compatible oxygenated liquid through said perfusion space by injecting said liquid into and withdrawing said liquid from said space.
Claim 2
Independent Claim 53 words
A method of treating retinal ischemia, comprising the steps of: a. removing at least a portion of the vitreous body to create an intra-ocular perfusion space; and b. establising a circulation of a physiologically compatible oxygenated liquid through said perfusion space by injecting said liquid into and withdrawing said liquid from said space.
Claim 3
Independent Claim 24 words
The method of claim I wherein said removing step comprises creating an incision at the limbus of the eye adjacent to the irido-corneal angle.
Claim 4
Dependent Claim 22 words
The method of claim 2 wherein said removing step comprises using an ultrasonic desecrator to remove a portion of the vitreous body.
Claim 5
Dependent Claim 22 words
The method of claim 1 wherein step (b) further comprises inserting input and output cannulae through the irido-corneal region of the eye.
Claim 6
Dependent Claim 20 words
The method of claim 1 wherein said circulation is established at a rate of between about 0.25 to 10 ml/min.
Claim 7
Dependent Claim 24 words
The method of claim 5 wherein said circulation is conducted at a pressure of no greater than the normal vitreous pressure of said eye.
Claim 8
Independent Claim 21 words
The method of claim I wherein step (b) comprises inserting an 18 to 25 gauge cannulae into said intraocular perfusion space.
Claim 9
Dependent Claim 30 words
The method of claim 1 wherein said oxygenated liquid is circulated for a duration and at a rate sufficient to support the aerobic metabolism of the retina until healing occurs.
Claim 10
Dependent Claim 19 words
The method of claim 1 further comprising the step of periodically circulating through said perfusion space a transparent solution.
Claim 11
Independent Claim 24 words
The method of claim I wherein said vitreous body is removed at least in the region adjacent to ischemic retinal tissue to be treated.
Claim 12
Dependent Claim 13 words
The method of claim 10 wherein said vitreous body is substantially completely removed.
Claim 13
Independent Claim 95 words
A method of diagnosing the condition of retinal tissue suspected of being ischemic, comprising the steps of: a. removing at least a portion of vitreous body to create an intracellular perfusion space adjacent to said retina; b. establishing a circulation of a physiologically compatible liquid of known composition through said space by injecting said liquid into contact with said tissue and withdrawing said liquid from said space; and c. analyzing said liquid withdrawn from said intraocular perfusion space to determine at least one characteristic of said withdrawn liquid which differs from said liquid as injected.
Claim 14
Independent Claim 95 words
A method of diagnosing the condition of retinal tissue suspected of being ischemic, comprising the steps of: a. removing at least a portion of vitreous body to create an intracellular perfusion space adjacent to said retina; b. establishing a circulation of a physiologically compatible liquid of known composition through said space by injecting said liquid into contact with said tissue and withdrawing said liquid from said space; and c. analyzing said liquid withdrawn from said intraocular perfusion space to determine at least one characteristic of said withdrawn liquid which differs from said liquid as injected.
Claim 15
Dependent Claim 30 words
The method of claim 12 wherein said method further comprises comparing constituents of said liquid for at least a selected difference in the composition of said injected and withdrawn liquids.
Claim 16
Dependent Claim 15 words
The invention of claim 13 wherein said selected difference is a difference in oxygen content.
Claim 17
Dependent Claim 16 words
The invention of claim 13 wherein said selected difference is a difference in lactic acid concentration.
Claim 18
Dependent Claim 16 words
The invention of claim 13 wherein said selected difference is a difference in carbon dioxide concentration.
Claim 19
Dependent Claim 15 words
The invention of claim 13 wherein said selected difference is a difference in ammonia concentration.
Claim 20
Dependent Claim 15 words
The invention of claim 13 wherein said selected difference is a difference in enzyme content.
Claim 21
Dependent Claim 13 words
The invention of claim 13 wherein said difference is a difference in pH.
Claim 22
Dependent Claim 13 words
The invention of claim 13 wherein said difference is a difference in GABA.
Claim 23
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in microorganism contents.
Claim 24
Dependent Claim 13 words
The invention of claim 21 wherein said microorganism content is a bacterial content.
Claim 25
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in ion concentration.
Claim 26
Dependent Claim 16 words
The invention of claim 23 wherein said ion concentration difference is a sodium ion concentration difference.
Claim 27
Dependent Claim 16 words
The invention of claim 23 wherein said difference is the difference in concentration of potassium ions.
Claim 28
Dependent Claim 15 words
The invention of claim 13 wherein said difference is a difference in amino acid concentration.
Claim 29
Dependent Claim 16 words
The invention of claim 13 wherein said difference is a difference in concentration of myelin fragments.
Claim 30
Dependent Claim 15 words
The invention of claim 13 wherein said difference is a difference in identifiable cellular materials.
Claim 31
Dependent Claim 17 words
The invention of claim 13 wherein said difference is a difference in concentration of identifiable cellular organelles.
Claim 32
Dependent Claim 13 words
The invention of claim 13 wherein said difference is a difference in protein.
Claim 33
Dependent Claim 13 words
The invention of claim 13 wherein said difference is a difference in fats.
Claim 34
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in fat content.
Claim 35
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in RNA content.
Claim 36
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in DNA content.
Claim 37
Dependent Claim 15 words
The invention of claim 13 wherein said difference is a difference in cellular metabolic products.
Claim 38
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in metabolite content.
Claim 39
Dependent Claim 14 words
The invention of claim 13 wherein said difference is a difference in neurotransmitter content.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-01-03 1992-07-04 1993-01-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-01-03 1996-07-04 1997-01-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-01-03 2000-07-04 2001-01-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag